PharmaVoice Spotlights GATC Health's Innovative Approach to Treat Addiction

"AI company zeros in on compounds to treat addiction by rewiring the brain"

Published Dec. 5, 2022

By Kelly Bilodeau

PharmaVoice, a leading industry publication delivering the most important voices and ideas in the life sciences to industry leaders, today featured GATC Health's efforts to fight opioid use disorder and fentanyl addiction. The article features company co-founder and Chief Science Officer Ian Jenkins and Tyrone Lam, GATC's Chief Operations Officer.

Excerpted from the story:One of the most insidious aspects of opioids is that they can change the brain by rewiring its circuitry, which drives addiction. GATC Health, a California-based science and technology company is exploring drugs that may be able to hit the reset button — fixing this faulty wiring and giving people with opioid use disorders and fentanyl addiction a fighting chance to kick the habit.“We believe we have discovered the core problem of addiction in the brain and have a novel solution that will help opioid addicts recover quicker and with greater benefits,” said GATC’s chief operating officer, Tyrone Lam.Read the full story

About GATC Health

GATC Health Corp is a science and technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC envisions the future of medicine now, where health is protected, disease is reversed and every person's unique biology is treated with precision.

GATC is accelerating the future of predictive, individualized medicine, today.